Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,928 shares of the company’s stock after selling 21,732 shares during the period. Victory Capital Management Inc. owned 0.05% of Medpace worth $5,624,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. State Street Corp increased its position in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC boosted its stake in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after buying an additional 44,371 shares during the period. Wellington Management Group LLP increased its position in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares during the last quarter. American Capital Management Inc. raised its stake in shares of Medpace by 2.6% in the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after acquiring an additional 9,592 shares during the period. Finally, GW&K Investment Management LLC lifted its holdings in shares of Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after acquiring an additional 133,379 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $324.95 on Friday. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock’s 50-day moving average is $340.28 and its two-hundred day moving average is $341.12. The company has a market cap of $9.90 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.